Last reviewed · How we verify
bepotastine besilate, 1.5%
At a glance
| Generic name | bepotastine besilate, 1.5% |
|---|---|
| Also known as | Bepreve |
| Sponsor | Southern California College of Optometry at Marshall B. Ketchum University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ (PHASE1)
- Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment (PHASE4)
- The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer (PHASE4)
- Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis (PHASE4)
- Comparing Patient Satisfaction With Pataday or Bepreve (NA)
- Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis (PHASE2, PHASE3)
- Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers (PHASE3)
- Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: